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Regulation of the protein kinase Raf-1 by oncogenic Ras through
phosphatidylinositol 3-kinase, Cdc42/Rac and Pak 
Huaiyu Sun*†, Alastair J. King†‡, H. Bruce Diaz*§ and Mark S. Marshall*†‡§
Activation of the protein kinase Raf-1 is a complex
process involving association with the GTP-bound form
of Ras (Ras–GTP), membrane translocation and both
serine/threonine and tyrosine phosphorylation (reviewed
in [1]). We have reported previously that p21-activated
kinase 3 (Pak3) upregulates Raf-1 through direct
phosphorylation on Ser338 [2]. Here, we investigated the
origin of the signal for Pak-mediated Raf-1 activation by
examining the role of the small GTPases Cdc42, Rac and
Ras, and of phosphatidylinositol (PI) 3-kinase. Pak3
acted synergistically with either Cdc42V12 or Rac1V12 to
stimulate the activities of Raf-1, Raf-CX, a membrane-
localized Raf-1 mutant, and Raf-1 mutants defective in
Ras binding. Raf-1 mutants defective in Ras binding were
also readily activated by RasV12. This indirect activation
of Raf-1 by Ras was blocked by a dominant-negative
mutant of Pak, implicating an alternative Ras effector
pathway in Pak-mediated Raf-1 activation. Subsequently,
we show that Pak-mediated Raf-1 activation is
upregulated by both RasV12C40, a selective activator of
PI 3-kinase, and p110-CX, a constitutively active PI
3-kinase. In addition, p85∆, a mutant of the PI 3-kinase
regulatory subunit, inhibited the stimulated activity of
Raf-1. Pharmacological inhibitors of PI 3-kinase also
blocked both activation and Ser338 phosphorylation of
Raf-1 induced by epidermal growth factor (EGF). Thus,
Raf-1 activation by Ras is achieved through a
combination of both physical interaction and indirect
mechanisms involving the activation of a second Ras
effector, PI 3-kinase, which directs Pak-mediated
regulatory phosphorylation of Raf-1.
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Results and discussions
To test whether Rac1 or Cdc42 alone could activate Raf-1
in intact cells, Rac1V12 or Cdc42V12 were coexpressed
with Raf-1 in COS7 cells, and Raf-1 activity measured.
Both Rac1V12 and Cdc42V12 reproducibly stimulated
Raf-1 activity by 4–5-fold (Figure 1a). In contrast,
RhoAV14, an activated version of the small GTPase
RhoA, did not significantly stimulate Raf-1, which is con-
sistent with the fact that Paks are not RhoA effectors. 
To determine whether activation of Raf-1 by Cdc42 or
Rac1 is mediated by Pak, wild-type Pak3 (Pak3wt) was
cotransfected with Raf-1 into COS7 cells. Although Pak3
alone did not significantly affect Raf-1 activation, a signifi-
cant activation of Raf-1 (20–30-fold) was observed when
Pak3 was cotransfected with Cdc42V12 or Rac1V12
(Figure 1a). This synergism in Raf-1 activation may be best
explained by activation of Pak3 by the small GTPases.
Pak3 and Cdc42V12 (Figure 1a) or Rac1 (data not shown)
together failed to stimulate a Raf mutant in which the
Ser338 residue has been substituted by Ala (RafA338),
indicating that Ser338 is critical for Pak-mediated Raf-1
activation. We reported previously [2] that Raf-CX cannot
be further activated by a constitutively active Pak3 mutant,
although it is still inhibited by a kinase-dead Pak3 mutant
(also shown in Figures 1b and 3a). Here, we found that
Cdc42V12 alone reproducibly stimulated Raf-CX to
1.8-fold of its basal activity, and that Cdc42V12 together
with Pak3wt enhanced Raf-CX activity by threefold (over
80-fold against Raf-1; Figure 1b). Consistent with previous
studies [3], our result suggests that Cdc42V12-stimulated
Pak3 is a more potent regulator than the constitutively
active Pak3 mutant with respect to Raf-1 activation. 
Several Raf-1 mutants that are defective in Ras binding
were also examined for responsiveness to Cdc42V12-acti-
vated Pak3 (Figure 2a). As an experimental control, wild-
type Raf-1, RafA84-87 and Raf-CR3 were coexpressed
with the RasV12S35 effector mutant. RasV12S35 has been
shown to preferentially bind and activate Raf-1 over other
Ras effector proteins [4]. Whereas wild-type Raf-1 was
activated by RasV12S35, neither RafA84-87 nor Raf-CR3
were significantly stimulated by this effector-selective Ras
mutant (Figure 2b). In contrast, the kinase activities of
both Ras-binding-defective Raf mutants were dramati-
cally stimulated by coexpression with Cdc42V12 and Pak3
together (Figure 2b). 
A similar activation profile was observed with two mem-
brane-targeted, Ras-binding-defective Raf mutants, Raf-
CXA84-87 and Raf-CXA84-87/S165,168 (Figure 2a,c).  In
the presence of Cdc42V12, both Raf-CX mutants showed
2–3-fold stimulation of basal activity, which increased an
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additional 2–3-fold by further coexpression with Pak3wt.
It may be inferred from our data that the activation of Pak
could potentially stimulate Raf-1 activity in the absence
of Ras–GTP. Ras-independent regulation of the extracel-
lular signal-regulated kinase (Erk) pathway has been doc-
umented in several biological processes such as
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Figure 1
GTPase-stimulated Pak3 activates Raf-1 and
Raf-CX, but not RafA338. (a) Raf-1 was
cotransfected into COS7 cells with an
active GTPase (Cdc42V12, Rac1V12 or
RhoAV14) and wild-type Pak3 (Pak3wt) in
the indicated combinations. As a control,
RafA338 was cotransfected either with
vector or with Cdc42V12 plus Pak3wt.
(b) Raf-CX was cotransfected with Pak3wt
or constitutively active Pak3 (Pak3ca, see
Supplementary material) and Cdc42V12 in
the indicated combinations. In this and the
following figures, kinase activity of the
Myc-epitope-tagged Raf-1 was assayed
3 days after transfection (see Supplementary
material). In these experiments, RasV12
alone induced as high as a 60–70-fold
activation of Raf-1 (data not shown). Data
shown are the average of at least three
independent transfections and duplicate
kinase assays. All stimulated Raf-1 kinase
activities were compared with basal
wild-type Raf-1 activity in each experiment
and are presented as fold activation.
Figure 2
Activation of Raf-1 in the absence of
Ras–GTP binding. (a) Raf-1 and Raf-CX
mutants defective for Ras binding are shown
schematically, with ‘X’ indicating the
mutation sites in conserved region 1 (CR1,
upper panel). The RafA84-87 mutant has a
defective Ras-binding domain (RBD) and
fails to bind Ras–GTP both in vivo and in
vitro [15,16]. Raf-CR3 lacks the entire
amino-terminal regulatory region containing
all known determinants of Ras association. In
addition to the RBD mutations, Raf-CXA84-
87/S165,168 has two Cys-to-Ser
substitutions in the cysteine-rich domain
(CRD), which has been demonstrated to
interact with regions of Ras distinct from the
effector loop [15]. Each protein was
expressed in COS7 cells with a Myc epitope
tag, was immunoprecipitated and detected
by immunoblotting with anti-Myc epitope
(9E10) antibody (lower panel).
Immunoglobulin G (IgG) heavy chain is from
the immunoprecipitation. (b) RafA84-87 and
Raf-CR3 were activated by Cdc42V12-
stimulated Pak3. RasV12S35-stimulated
activities of Raf-1 and mutants are shown as
a control. (c) Activation of membrane-
targeted Ras-binding-defective mutants Raf-
CXA84-87 and Raf-CXA84-87/S165,168 by
Cdc42V12-stimulated Pak3.
(d) Pak-mediated activation of Raf-CX and
its Ras-binding-defective forms, Raf-CXA84-
87 and Raf-CXA84-87/S165,168, by
oncogenic Ras. All stimulated Raf-1 activities
shown here are the average of at least three
independent experiments and are presented
as fold activation compared with basal wild-
type Raf-1 activity. 
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integrin-mediated signaling [5], mitosis [6] and signaling of
some G-protein-coupled receptors [7]. Full activation of
Raf-1 is the cooperative effort of multiple processes. Never-
theless, different degrees of Raf-1 activity in normal cells
can result in very different outcomes [8], demonstrating the
need for stepwise control of the Raf kinases. Ras-indepen-
dent activation of Raf-1 by serine/threonine or tyrosine
kinases could be one way of achieving a minimal degree of
activation under conditions when full activation of the Ras
pathway is undesirable.
Here and in previous studies, we noticed that the mea-
sured activity of Raf-CX was reproducibly lower than that
of wild-type Raf-1 stimulated by RasV12, typically one-
third to one-half that of RasV12-stimulated wild-type
Raf-1 [9]. Coexpression of RasV12 with Raf-CX further
increased the kinase activity of Raf-CX (Figure 2d). This
phenomenon may indicate that the role of Ras in Raf acti-
vation is not limited to targeting Raf to the plasma mem-
brane. In addition to membrane recruitment, the
contribution of Ras towards Raf-1 activation may be the
conformational change of a membrane-targeted Raf-1
molecule induced by Ras binding [1]. Additionally,
crosstalk between another Ras effector pathway and
Raf-1 might also act to modulate the level of kinase sig-
naling following membrane localization of Raf-1. We
observed that, although unable to associate with Ras, the
Raf-CXA84-87 or Raf-CXA84-87/S165,168 mutants were
efficiently activated by RasV12 (Figure 2d). These results
argue that oncogenic Ras can indeed activate a Raf-1
modulatory pathway, independent of any physical associ-
ation between the two proteins. Moreover, the RasV12
activation of all three membrane-targeted forms of Raf-1
was inhibited by cotransfecting a kinase-dead Pak mutant
(Pak3dn; Figure 2d), indicating that Pak serves as one
downstream component of Ras signaling that can promote
Raf-1 activation. 
Our data suggest a model in which Ras triggers a Pak-
dependent pathway to increase Raf-1 activity beyond that
obtained strictly through a Ras–Raf interaction. As also
found in the Drosophila Torso signaling pathway, Ras1 is
required for the function of a truncated Draf CR3 lacking
the RBD and CRD regions [10]. Therefore, the function of
Ras in Raf activation is not only to interact physically with
the protein kinase through the RBD/CRD, but also to acti-
vate a second component, which acts directly on the cat-
alytic domain. Among the Ras effectors, PI 3-kinase has
been reported to regulate the activation of Rho family small
GTPases through Dbl family guanine-nucleotide exchange
factors (GEF) [11]. The observation that Cdc42 and Rac1
readily stimulated Raf-1 activity suggested that PI 3-kinase
might be the second Ras effector acting upstream to regu-
late the Pak-dependent Raf-1 activation [12]. 
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Figure 3
Pak-mediated regulation of Raf-1 by PI
3-kinase. (a) Left, wild-type Raf-1 or RafA338
was coexpressed with RasV12C40 in the
absence or presence of Pak3wt. Right,
inhibition of RasV12C40-stimulated Raf-1 or
Raf-CX alone by either kinase-dead Pak3
(Pak3dn) or the dominant-negative PI 3-
kinase regulatory subunit, p85∆.
(b) Raf-CXA84-87 was expressed alone or in
combination with p110-CX, an active form of
PI 3-kinase, in the absence or presence of
Pak3dn, Cdc42N17, or Rac1N17. (c) COS7
cells expressing Raf-1 or Raf-CXA84-87 were
treated with 100 ng/ml EGF (similar results
were obtained with 10 ng/ml EGF) for 10 min
after the cells were incubated with DMSO,
wortmannin (Wm, 100 nM) or LY294002 (LY,
100 µM). Myc–Raf-1 kinase activity was then
measured as described. Data presented are
the average of the results from three assays.
(d) COS7 cells were harvested after
stimulation with 10 ng/ml EGF in the
presence or absence of wortmannin
(10–100 nM) or LY294002 (10–100 µM).
Raf-1 protein was immunoprecipitated with
anti-Raf-1 antibody and probed first with anti-
phosphoSer338 antibody (upper panel) and
then re-probed with anti-Raf-1 antibody (lower
panel; see Supplementary material). The
result shown here is from one representative
experiment. The relative phosphorylation
levels were determined by densitometric
scanning of both anti-phosphoSer338 and
anti-Raf-1 immunoblots.
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To address this hypothesis, we first examined a PI
3-kinase-selective Ras effector mutant, RasV12C40, for its
ability to stimulate Raf-1. RasV12C40 has been shown to
interact with the PI 3-kinase p110 catalytic subunit but not
with Raf or RalGDS [4]. Coexpression of RasV12C40 with
wild-type Raf-1 resulted in a ten-fold activation of kinase
activity. This activation was Ser338 dependent and was
enhanced by Pak3wt and inhibited by Pak3dn (Figure 3a).
Next, we tested the sensitivity of Raf-1 activation to p85∆,
a deletion mutant of the PI 3-kinase regulatory subunit,
which is defective in association with the PI 3-kinase cat-
alytic subunit [13] and functions as a dominant inhibitor of
PI 3-kinase [14]. We found that the coexpression of p85∆
with Raf-CX or RasV12C40 and Raf-1 caused a 50% reduc-
tion of Raf kinase activity (Figure 3a). As supporting evi-
dence, coexpression of a constitutively active PI 3-kinase,
p110-CX [14], with Raf-CXA84-87 resulted in a twofold
activation of this Raf mutant. Activation by p110-CX was
blocked by coexpression with Cdc42N17, Rac1N17 or
Pak3dn (Figure 3b), suggesting that PI 3-kinase upregu-
lates Raf-1 through Cdc42/Rac1 and Pak. 
We further investigated the involvement of PI 3-kinase in
Raf-1 activation using two pharmacological inhibitors of PI
3-kinase, wortmannin and LY294002. In COS7 cells, a
15-fold activation of Raf-1 was obtained by stimulating the
cells with EGF. This activation was significantly reduced
when wortmannin or LY294002 was present during EGF
stimulation (Figure 3c), or when Pak3dn was coexpressed
with Raf-1 (data not shown). The stimulation of Raf-
CXA84-87 by EGF was also attenuated by wortmannin or
LY294002 (Figure 3c), demonstrating regulation of Raf-1
by PI 3-kinase independent of a Ras–Raf-1 interaction.
Furthermore, we determined the extent of phosphorylation
of Raf-1 on serine 338 in EGF-treated COS7 cells using a
specific anti-phosphoSer338 antiserum. As shown in
Figure 3d, phosphorylation of Raf-1 Ser338 was signifi-
cantly induced upon EGF stimulation. Both wortmannin
and LY294002 effectively inhibited EGF-induced Ser338
phosphorylation in a dose-dependent manner, suggesting
that Ser338 phosphorylation is regulated by PI 3-kinase
(Figure 3d). We conclude from the above results that
activated Ras does in fact increase the degree of Raf-1
kinase activation through crosstalk through a PI 3-
kinase–Cdc42/Rac–Pak signaling pathway (as depicted
in the Supplementary material).
The signal connection between Ras and Raf-1 thus appears
to be both direct and indirect. Physical association between
the two proteins results in membrane localization of Raf-1
as well as a conformational change favorable to kinase acti-
vation. Through the stimulation of a second Ras effector, PI
3-kinase, Ras activates a Cdc42/Rac-coupled signal trans-
duction cascade which stimulates the Pak protein kinases.
Pak phosphorylates Ser338 in the Raf-1 catalytic domain,
resulting in potent activation of Raf-1 kinase activity. In this
way, the cell can closely regulate the degree of Raf-1 kinase
activity through multiple levels of control: Ras–GTP, PI
3-kinase, Cdc42–GTP/Rac–GTP and Pak. 
Supplementary material
Additional results and discussion, additional methodological details
and a model for the dual role of Ras in regulating the Raf-1 kinase are
available at http://current-biology.com/supmat/supmatin.htm.
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